Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis

被引：0

作者：

Neville-Webbe H.L. ^{[1
]}

Cross N.A. ^{[2
]}

Eaton C.L. ^{[2
]}

Nyambo R. ^{[2
]}

Evans C.A. ^{[1
]}

Coleman R.E. ^{[1
]}

Holen I. ^{[1
]}

机构：

[1] Clinical Oncology, Division of Genomic Medicine, Sch. Med. Biol. Sci.

[2] Academic Unit of Urology, Division of Clinical Sciences, Sch. Med. Biol. Sci.

来源：

Breast Cancer Research and Treatment | 2004年 / 86卷 / 3期

关键词：

apoptosis; bone marrow stromal cells; bone metastases; breast cancer; OPG; TRAIL-induced apoptosis;

D O I：

10.1023/B:BREA.0000036900.48763.b3

中图分类号：

学科分类号：

摘要：

Advanced breast cancer is often associated with metastatic bone disease, causing a number of serious complications for the patients such as hypercalceamia, pain, nerve compression and fractures. The formation of bone metastases depends on complex interactions between tumour cells and the cells of the bone microenvironment, but the precise molecular mechanisms involved in the development of tumour-induced bone disease have not been identified. We have investigated the ability of bone marrow stromal cells (BMSC) isolated from breast cancer patients to generate osteoprotegerin (OPG), a molecule involved both in bone turnover and cell survival. The potential survival effects of OPG are mediated through binding to a member of the TNF super family, TNF-related Apoptosis Inducing Ligand (TRAIL), preventing association between TRAIL and its death-inducing receptors present on a number of tumour cell types. In the present report we show that bone marrow stromal cells isolated from breast cancer patients produce OPG when grown in culture. The levels of OPG present in BMSC conditioned medium is sufficient to protect breast cancer cells from undergoing TRAIL induced apoptosis. Our data suggest that bone-derived OPG may increase survival of breast cancer cells that reach the bone microenvironment as part of the metastatic process.

引用

页码：269 / 279

页数：10

共 16 条

[1]

Mundy G.R., Metastasis to bone: Causes, consequences and therapeutic opportunities, Nat. Rev. Cancer., 8, pp. 584-593, (2002)

[2]

Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morianga T., Higashio K., Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis, Biochem. Biophys. Res. Comm., 234, pp. 137-142, (1997)

[3]

Simmonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliot R., Colombero A., Tan H.L., Trail G., Sullivan J., Davey E., Bucay N., Renshaw-Gregg L., Hughes T.M., Hill D., Pattison W., Campbell P., Boyle W.J., Osteoprotegrin: A novel secreted protein involved in the regulation of bone density, Cell, 89, pp. 309-319, (1997)

[4]

Khosla S., The OPG/RANKL/RANK system, Minireview: Endocrinol, 142, pp. 5050-5055, (2001)

[5]

Zhang J., Qi Y., Lin D., Smith P., Strayhorn C., Mizokam A., Fu Z., Westman J., Keller E.T., Osteoprotegerin inhibits prostate cancer induced osteoclastogenesis and prevents prostate tumour growth in the bone, J. Clin. Investig., 107, pp. 1235-1244, (2001)

[6]

Morony S., Capparelli C., Sarosi I., Lacey D.L., Dunstan C.R., Kostenuik P.J., Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis, Cancer Res., 61, 11, pp. 4432-4436, (2001)

[7]

Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenburg M., Lee J.C., Young P.R., Osteoprotegrin is a receptor for cytotoxic ligand TRAIL, J. Biol. Chem., 273, pp. 14363-14367, (1998)

[8]

Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A., Induction of apoptosis by Apo-2 ligand, a new member of the tumour necrosis factor cytokine family, J. Biol. Chem., 271, pp. 12687-12690, (1996)

[9]

Takeda K., Smyth M.J., Cretney E., Hayakawa Y., Kayagaki N., Hideo Yagita H., Okumura K., Critical role for tumour necrosis factor-related apoptosis inducing ligand in immune surveillance against tumour development, J. Exp. Med., 195, pp. 161-169, (2002)

[10]

Sheridan P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramarkrishnan L., Gray C.L., Baker K., Wood W.I., Goddard A.D., Godowski P., Ashkenazi A., Control of TRAIL induced apoptosis by a family of signalling and decoy receptors, Science, 277, pp. 818-821, (1997)

← 1 2 →